Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study assessing the safety of SM17, a first-in-class asthma therapy, in the Chinese population. The study will also explore the clinical development plan for SM17 in the treatment of allergic diseases.
SM17: A Novel Approach to Asthma and Allergic Disease Treatment
SM17 is a groundbreaking therapy that works by suppressing Th2 immune responses. It achieves this by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), effectively blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine known as an “alarmin,” which has been implicated in the pathogenesis of airway viral responses and allergic diseases. By targeting IL-25, SM17 has the potential to offer a new treatment option for patients suffering from asthma and other allergic conditions.
Clinical Development Plan for SM17 in Allergic Diseases
The clinical development plan for SM17 includes not only the assessment of its safety in asthma patients but also its potential efficacy in treating allergic diseases. This comprehensive approach underscores SinoMab BioScience’s commitment to advancing innovative therapies that address a broad range of respiratory and allergic conditions.-Fineline Info & Tech
